Sanofi Receives CHMP Recommendation for Dupixent Expansion in Europe

Why It Matters

The expanded indication opens a sizable new market segment and addresses an unmet therapeutic need for children who fail standard antihistamine therapy, strengthening Sanofi‑Regeneron’s position in the biologics arena.

Key Takeaways

• CHMP recommends Dupixent for children 2‑11 with CSU
• Approval targets moderate‑to‑severe cases unresponsive to antihistamines
• LIBERTY‑CUPID Phase III data underpin recommendation
• US FDA decision expected by April 2026
• Expands Sanofi‑Regeneron’s type 2 inflammation portfolio

Pulse Analysis

Chronic spontaneous urticaria (CSU) affects millions of children worldwide, often persisting despite first‑line antihistamines. The condition not only impairs quality of life but also places a burden on families and healthcare systems. Dupixent, a monoclonal antibody that blocks interleukin‑4 and interleukin‑13 signaling, offers a targeted approach that does not suppress the immune system, making it an attractive option for paediatric patients who need more than symptomatic relief.

The CHMP’s positive opinion follows the LIBERTY‑CUPID clinical programme, which delivered statistically significant reductions in hive counts and itch severity across two Phase III trials and a single‑arm study. These data demonstrated safety and efficacy in children as young as two, meeting the stringent criteria of European regulators. While the final EU approval is pending, the agency’s recommendation accelerates market entry. In parallel, the U.S. Food and Drug Administration is reviewing a supplemental biologics licence application, with a decision slated for April 2026, indicating a coordinated global rollout strategy.

For Sanofi and Regeneron, the pediatric CSU label expands an already extensive type 2 inflammation portfolio that includes asthma, atopic dermatitis, and eosinophilic esophagitis. The new indication taps into a multi‑billion‑dollar market, bolstering revenue forecasts and reinforcing the companies’ leadership in biologic therapeutics. Moreover, the success of Dupixent in this niche may catalyse further investigations into related allergic disorders, positioning the partnership for sustained growth in a competitive biotech landscape.